Edition:
United Kingdom

Eagle Pharmaceuticals Inc (EGRX.OQ)

EGRX.OQ on NASDAQ Stock Exchange Global Market

55.12USD
25 Apr 2018
Change (% chg)

-- (--)
Prev Close
$55.12
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
96,157
52-wk High
$97.14
52-wk Low
$45.05

Chart for

About

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its... (more)

Overall

Beta: 1.32
Market Cap(Mil.): $817.56
Shares Outstanding(Mil.): 14.86
Dividend: --
Yield (%): --

Financials

  EGRX.OQ Industry Sector
P/E (TTM): 15.85 29.67 32.21
EPS (TTM): 3.48 -- --
ROI: 27.94 13.44 13.05
ROE: 33.50 15.16 14.90

BRIEF-Eagle Pharmaceuticals’ Vasopressin ANDA Accepted For Filing By The FDA

* EAGLE PHARMACEUTICALS’ VASOPRESSIN ANDA ACCEPTED FOR FILING BY THE FDA

16 Apr 2018

BRIEF-Eagle Pharmaceuticals - Announced Co's Eagle Biologics Division Has Been Issued A New Patent

* EAGLE PHARMACEUTICALS - ANNOUNCED CO'S EAGLE BIOLOGICS DIVISION HAS BEEN ISSUED A NEW PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

27 Mar 2018

BRIEF-Eagle Pharmaceuticals Reports Q4 EPS Of $0.58

* EAGLE PHARMACEUTICALS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS

26 Feb 2018

BRIEF-Iridian Asset Management LLC Reports 10.1 Pct Passive Stake In Eagle Pharmaceuticals As Of Dec. 31, 2017 - SEC Filing‍​

* IRIDIAN ASSET MANAGEMENT LLC REPORTS 10.1 PERCENT PASSIVE STAKE IN EAGLE PHARMACEUTICALS INC AS OF DEC. 31, 2017 - SEC FILING‍​ Source text: (http://bit.ly/2En48mt) Further company coverage:

08 Jan 2018

BRIEF-Iridian Asset Management Reports 10.1 Pct Passive Stake In Eagle Pharmaceuticals

* IRIDIAN ASSET MANAGEMENT REPORTS 10.1 PERCENT PASSIVE STAKE IN EAGLE PHARMACEUTICALS AS OF DEC 31, 2017 - SEC FILING‍​ Source text: (http://bit.ly/2AG5uGB) Further company coverage:

08 Jan 2018

BRIEF-Eagle Pharmaceuticals Commences Pivotal Study For Fulvestrant

* EAGLE PHARMACEUTICALS COMMENCES PIVOTAL STUDY FOR FULVESTRANT

07 Dec 2017

BRIEF-Eagle Pharmaceuticals Q3 earnings per share $0.98

* Eagle Pharmaceuticals Inc reports third quarter 2017 results

08 Nov 2017

Eagle Pharma gets tentative FDA approval for Lilly's Alimta version

Eagle Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration tentatively approved its diluted version of Eli Lilly and Co's blockbuster cancer drug Alimta.

27 Oct 2017

UPDATE 1-Eagle Pharma gets tentative FDA approval for Lilly's Alimta version

Oct 27 Eagle Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration tentatively approved its diluted version of Eli Lilly and Co's blockbuster cancer drug Alimta.

27 Oct 2017

FDA tentatively approves Eagle Pharma's cancer drug

Oct 27 Eagle Pharmaceuticals Inc said on Friday that the U.S. Food and Drug Administration tentatively approved its injectable drug to treat a most common type of lung cancer and a cancer of mesothelial tissue.

27 Oct 2017

Earnings vs. Estimates